Diabetic macular edema (DME) threatens the sight of more than half of individuals who suffer from diabetes for twenty years or more. It is estimated that 21 million people world-wide are afflicted by DME, and these numbers are expected to grow as the rate of diabetes escalates globally.

In DME, the progression towards blindness is typically associated with degeneration and dysfunction of the retinal vascular system. The plasma kallikrein-kinin system is activated during vascular injury where it mediates inflammation, blood circulation, and coagulation. Verseon has developed a series of plasma kallikrein inhibitors as a potential treatment of DME and other related eye disorders. These treatments would be delivered by eye drops, an improvement over standard treatments which require regular eye injections

Verseon's plasma kallikrein inhibitors are potent in functional and in vitro assays. In addition, these drug candidates have sufficient transcorneal permeability to be administered as eye drops.

Our current drug portfolio spans four separate therapeutic areas, all with unmet (or poorly met) medical needs


Current Pipeline

First-in-class oral anticoagulants for cardiovascular indications

Kallikrein inhibitors for the treatment of diabetic macular edema

Kallikrein inhibitors for the treatment of hereditary angioedema

Novel angiogenesis inhibitors for the treatment of solid tumors